Olaparib Toxicity Profile
Hematologic Toxicities
- Grade ≥3 anemia occurs in 5-22% of patients receiving olaparib monotherapy 1, 2, 3
- When combined with bevacizumab, grade ≥3 anemia occurs in 17% of patients 1, 2
- Any-grade anemia ranges from 39-41% in ovarian cancer maintenance trials 5, 6
- Grade ≥3 neutropenia occurs in 9% of olaparib-treated patients 5, 6
- Any-grade neutropenia occurs in 23% of patients 6
- Grade ≥3 thrombocytopenia is rare with olaparib monotherapy (1-2%) 5, 6
- Olaparib causes significantly less neutropenia and thrombocytopenia compared to niraparib (which has 19.6% grade ≥3 neutropenia and 34% grade ≥3 thrombocytopenia) 1, 2, 3
Non-Hematologic Toxicities
- Nausea occurs in 43-77% of patients (any grade), but grade ≥3 nausea is rare (<5%) 5, 6
- Vomiting occurs in 40% of patients (any grade), with grade ≥3 in approximately 1% 5, 6
- Fatigue/asthenia occurs in 42-63% of patients (any grade) 5, 6
- Grade ≥3 fatigue is uncommon with olaparib monotherapy (approximately 4%) 5
- Constipation occurs in 28% of patients 5
- Diarrhea and dysgeusia are less common 6
Rare but Serious Toxicities
- MDS/AML occurs in ≤2% of patients across trials 7, 8
- Venous thromboembolic events are a rare but serious adverse effect 9
- Pulmonary emboli are specifically noted as rare but serious adverse effects 9
- Drug-induced pneumonitis occurs in approximately 2% of patients 9, 10
Treatment Discontinuation and Dose Modifications
- Overall discontinuation due to adverse events occurs in 11.5-12% of patients with olaparib monotherapy 5, 6
- When combined with bevacizumab, discontinuation rates increase to 20% 6
- Hematologic toxicities are the most common cause of dose reductions and treatment discontinuation 7, 8
Quality of Life Impact
- Despite the toxicity profile, olaparib does not negatively impact health-related quality of life compared to placebo 2, 3, 11
- Quality of life scores remain comparable between treatment groups throughout maintenance therapy 2, 3